Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain up take of brain-derived neurotrophic factor following intravenous administration

Pharmaceutical Research

Volumn 15, Issue 4, 1998, Pages 576-582

  Pardridge, William M ^a   Wu, Dafang ^a   Sakane, Toshiyasu ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Blood brain barrier; Pegylation; Pharmacokinetics

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; MACROGOL; STREPTAVIDIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONJUGATE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG TRANSPORT; DRUG UPTAKE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEMBRANE PERMEABILITY; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOTIN; BLOOD-BRAIN BARRIER; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; DRUG DELIVERY SYSTEMS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MICE; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, TRANSFERRIN; RECOMBINANT PROTEINS;

EID: 0031901771     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011981927620     Document Type: Article

References (21)

1. M. B. Spina, S. P. Squinto, J. Miller, R. M. Lindsay, and C. Hyman. Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and n-methyl-4-phenylpyridinium ion toxicity-involvement of the glutathione system. J. Neurochem. 59:99-106 (1992).
2. F. Hefti. Pharmacology of neurotrophic factors. Annu. Rev. Pharmacol. Toxicol. 37:239-267 (1997).
3. W. M. Pardridge, W.-S. Kang, and J. L. Buciak. Transport of human recombinant brain-derived neurotrophic factor (BDNF) through the rat blood-brain barrier in vivo using vector-mediated peptide drug delivery. Pharm. Res. 11:738-746 (1994).
4. T. Sakane and W. M. Pardridge. Carboxyl-directed pegylation of brain-derived neurotrophic factor markedly reduces systemic clearance with minimal loss of biologic activity. Pharm. Res. 14:1085-1091 (1997).
5. W. M. Pardridge. Drug delivery to the brain. J. Cereb. Blood Flow Metabol. 17:713-731 (1997).
6. W. A. Jefferies, M. R. Brandon, S. V. Hunt, A. F. Williams, K. C. Gatter, and D. Y. Mason. Transferrin receptor on endothelium of brain capillaries. Nature. 312:162-163 (1984).
7. W. M. Pardridge, J. Eisenberg, and J. Yang. Human blood-brain barrier transferrin receptor. Metabolism. 36:892-895 (1987).
8. W. M. Pardridge, J. L. Buciak, and P. M. Friden. Selective transport of anti-transferrin receptor antibody through the blood-brain barrier in vivo. J. Pharmacol. Exp. Ther. 259:66-70 (1991).
9. U. Bickel, Y.-S. Kang, T. Yoshikawa, and W. M. Pardridge. In vivo demonstration of subcellular localization of anti-transferrin receptor monoclonal antibody-colloidal gold conjugate within brain capillary endothelium. J. Histochem. Cytochem. 42:1493-1497 (1994).
10. 125I]-transferrin through the rat blood-brain barrier in vivo. Brain Res. 683:164-171 (1995).
11. M. B. Rosenberg, E. Hawrot, and X. O. Breakefield. Receptor binding activities of biotinylated derivatives of β-nerve growth factor. J. Neurochem., 46:641-648 (1986)
12. W. M. Pardridge. Vector-mediated peptide drug delivery to the brain. Adv. Drug Del. Rev. 15:109-146 (1995).
13. L. O. Narhi, R. Rosenfeld, J. Talvenheimo, S. J. Prestrelski, T. Arakawa, J. W. Lary, C. G. Kolvenbach, R. Hecht, et al. Comparison of the biophysical characteristics of human brain-derived neurotrophic factor, neurotrophin-3, and nerve growth factor. J. Biol. Chem. 268:13309-13317 (1993).
14. T. Arakawa, M. Haniu, L. O. Narhi, J. A. Miller, J. Talvenheimo, J. S. Philo, H. T. Chute, C. Matheson, et al. Formation of heterodimers from three neurotrophins, nerve growth factor, neurotrophin-3, and brain-derived neurotrophic factor. J. Biol. Chem. 269:27833-27839 (1994).
15. N. M. Green. Avidin. Adv. Prot. Chem. 29:85-133 (1975).
16. D. J. Glass, S. H. Nye, P. Hantzopoulos, M. J. Macchi, S. P. Squinto, M. Goldfarb, and G. D. Yancopoulos. TRKB mediates BDNF/NT-3-dependent survival and proliferation in fibroblasts lacking the low affinity NGF receptor. Cell. 66:405-413 (1991).
17. B. Honig and A. Nicholls. Classical electrostatics in biology and chemistry. Science 268:1144-1149 (1995).
18. C. F. Ibáñez, T. Ebendal, G. Barbany, J. Murray-Rust, T. L. Blundell, and H. Persson. Disruption of the low affinity receptor-binding site in NGF allows neuronal survival and differentiation by binding to the TRK gene product. Cell 69:329-341 (1992).
19. J. Huwyler, D. Wu, W. M. Pardridge. Brain drug delivery of small molecules using immunoliposomes. Proc Natl. and Acad Sci U.S.A. 93:14164-14169 (1996).
20. D. Wu, Y.-S. Kang, U. Bickel, and W. M. Pardridge. Blood-brain barrier permeability to morphine-6-glucuronide is markedly reduced compared to morphine. Drug Metab. Disp. 25:768-771 (1997).
21. U. Bickel, T. Yoshikawa, and W. M. Pardridge. Delivery of peptides and proteins through the blood-brain barrier. Adv. Drug Del. Rev. 10:205-245 (1993).